Phenotypes Associated with This Genotype

Genotype
MGI:5781131

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO-EGFR*T790M*L858R)19Kkw/0
• Genetic Background: involves: 129 * C57BL/6 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

interstitial pneumonia ( J:122849 )

• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors

neoplasm

increased metastatic potential ( J:122849 )

• metastatic foci of adenocarcinomas are occasionally seen in lymph nodes of doxycycline treated mice

increased lung tumor incidence ( J:122849 , J:156440 , J:235747 )

• mice develop lung tumors after 5-6 weeks of doxycycline administration (J:122849)

• early lesions develop in alveoli after 2-3 weeks of doxycycline administration (J:122849)

• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal (J:122849)

• mice treated with the WZ4002 compound show an increase in cell apoptosis and decrease in cell proliferation and regression of tumors (J:156440)

• mice treated together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab show regression of tumors, however treatment alone with EAI045 has no effect on tumors (J:235747)

• treatment alone with cetuximab has a minimal effect on tumor regression (J:235747)

increased lung carcinoma incidence ( J:122849 )

• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration

increased lung adenocarcinoma incidence ( J:122849 )

• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment

• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment

• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment

• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment

• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin

respiratory system

interstitial pneumonia ( J:122849 )

• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors

increased lung tumor incidence ( J:122849 , J:156440 , J:235747 )

• mice develop lung tumors after 5-6 weeks of doxycycline administration (J:122849)

• early lesions develop in alveoli after 2-3 weeks of doxycycline administration (J:122849)

• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal (J:122849)

• mice treated with the WZ4002 compound show an increase in cell apoptosis and decrease in cell proliferation and regression of tumors (J:156440)

• mice treated together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab show regression of tumors, however treatment alone with EAI045 has no effect on tumors (J:235747)

• treatment alone with cetuximab has a minimal effect on tumor regression (J:235747)

increased lung carcinoma incidence ( J:122849 )

• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration

increased lung adenocarcinoma incidence ( J:122849 )

• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment

• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment

• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment

• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment

• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:122849 , J:156440 , J:235747